Clinical trial

LAG3 Expression in Triple Negative Breast Cancer

NCT06259162

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-11-18

PhaseNA

Study timeline

Study start (actual)2022-11-18Date precision: day

Registry last updated2024-02-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple Negative Breast Cancerunresolved

Immune Checkpoint Inhibitorunresolved

Interventions

LAG-3 expression / immune checkpoint protein expressionPROCEDURE

Sponsors & collaborators

Samsung Medical Centerlead sponsor

Mapped research locations

SeoulSouth Korea1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06259162 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.